Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Inpatient, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-3463275 In Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

NCT00567203 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00567203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00567203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Inpatient, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-3463275 In Adjunctive Treatment Of Cognitive Deficits In Schizophrenia
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2007
Completion date
May 31, 2008
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia